Available online www.jocpr.com

Journal of Chemical and Pharmaceutical Research, 2016, 8(4):919-927

Research Article

ISSN : 0975-7384
CODEN(USA) : JCPRC5

Human malignancy associated with Y chromosome: Genotypes and haplotypes associated with susceptibility to Colorectal Cancer patients

Ali H. Al-Marzoqi*, Hawraa J. Kadhim, Ammal R. Shimran, Nebras M. Al-Khafaji, Sabreen A. Kamal, Rusul Adil Naji, Zubaida Amer Faisal, Sarah Abbas Fakhri and Redaah Abd-Alrazzak

College of Science for Women, Babylon University, Iraq

ABSTRACT

Methylenetetrahydrofolate reductases (MTHFR) considered as a critical character in digestion system of folate furthermore collaborate with union of nucleic corrosive, repair arrangement of DNA and methylation. Our revision was meant to reveal essence concerning polymorphism in MTHFR gene in addition to the CRC danger. The study populace included 77 disease male patients with CRC (mean of age in years 64±8.7) separated as; (41 with colon malignancy and 36 with rectal growth) and 55 as controls admitted to the Merjan Healing center in span stretched out from October 2015 until March 2016. The outcomes uncovered that hereditary polymorphisms of all qualities incorporating into this study for MTHFR 677 quality in CRC patients; the recurrence of MTHFR C677 genotypes were as kindred TT 12.0 (15.6%), CT 24.0 (31.2%), and CC 41.0 (53.2%) in CRC, and in the control was 19.0 (34.5%), 14.0 (25.5%), and 22.0 (40.0%) individually. Amalgamation frequencies for MTHFR 677 TT homozygous and CT 677 heterozygous watched were 31.2% in CRC and 47.3% in the controls. The Genotype dissemination for MTHFR 1298 quality in CRC patients; the recurrence of MTHFR C677 genotypes were as kindred CC 9.0 (11.7%), CA 21.0 (27.3%), and AA 47.0 (61%) in CRC, while in the control was as individual 8.0 (14.5%), 21.0 (38.2%), and 26.0 (47.3%) separately. The recurrence for MTHFR 1298 quality AA homozygous and AC 1298 heterozygous watched was 74.7% in CRC and 66.4% in the controls. Spreading of genotype for XRCC1 399 quality in CRC patients; the Genotype conveyance for this quality in CRC patients; the recurrence of XRCC1 399 genotypes were as kindred TT 28.0 (36.4%), TG 13.0 (16.9%), and GG 36.0 (46.8%) in CRC, while in the control was as individual 27.0 (49.1%), 6.0 (10.9%), and 22.0 (40%) separately. The recurrence for XRCC1 399 quality TT homozygous and TG 399 heterozygous watched were 44.87% in CRC and 45.45% in the controls. MTHFR; XRCC1 SNPs is connected with expanded CRC hazard.

Keywords: Y-chromosome; CRC; Genotype; Haplotype; MTHFR; XRCC1.

INTRODUCTION

Loss of Y chromosome [LOY] is a surely understood marvel that is connected with maturing and saw with fluctuating frequencies in bone marrow cells [1,2] or in fringe platelets [3,4]from sound more established male. The relationship of LOY with hematological growths has been subtle. Be that as it may, LOY has been accounted for in leukemia [5-8] and in patients anticipated to have poor reaction to tumor treatment [9]. Different studies have found the affiliation just in patients who demonstrated LOY in more than 75% [10] or 100% of the influenced cells [11].

Various studies have recognized different sex contrasts in the dangers, frequency and progression of different human infections, for example, asthma [12, 13] immune system ailments [14, 15], schizophrenia [16, 17], a mental imbalance range issue [18, 19], cardiovascular illness [20, 21] and non-sex-particular growths, for example, liver disease, bladder tumor, and lung malignancy [22-24]. As per the report by Cook and partners, 32 out of 36 disease sorts indicated male inclination of malignancy mortality in United States for the years somewhere around 1977 and

2006 [25]. Be that as it may, the instruments in charge of such sex‐differences are still to a great extent obscure. The most noteworthy hereditary contrasts in the middle of men and ladies are qualities on their sex chromosomes, that is, XY for men and XX for ladies. Men are inclined to X-connected ailments brought on by transformations on qualities on their X chromosome while ectopic articulation of the qualities on their Y chromosome could have male‐specific impacts on ordinary advancement, physiology, and illnesses. The human Y chromosome can be grouped basically into three districts: the Y chromosome of male exact locale [MSY], pseudoautosomal areas [PAR1 and PAR2], and heterochromatin locale on Yq.26 PARs contain 20 protein‐coding qualities [16 qualities in PAR1 and 4 qualities in PAR2] that are additionally present on the X chromosome. The MSY contains 23 protein‐coding qualities and various pseudogenes [27-29]. While qualities in PARs are available in both X and Y chromosomes and experience meiotic recombination comparatively with autosomal qualities, qualities in MSY are avoided from meiotic recombination with a homologous chromosome accomplice. The MSY qualities advanced amid around 300 million years in the wake of start of X‐Y separation [30].

Colorectal Cancer (CRC) has known a complex polygenic issue which would be a standout amongst the most known reasons for mortality in men [31]. Albeit late studies have distinguished various variations, quality combinations, and expression marks have partnered with prostate tumor, then ID and portrayal of qualities that have included in this growth, has stayed as a considerable test [32]. The many-sided quality and multigenic nature of growth has brought about different extensive studies, have been accomplishing a frameworks level comprehension of the key hereditary arbiters, included in prostate malignancy [33]. One point of convergence in growth examination would be the reproduction of co-expression systems. Whenever exact, co-expression systems have spoken to the key middle people that have included in a particular procedure. The accessibility of the far reaching quality expression information has helped the advancement of different condition of-workmanship co-expression systems reproduction strategies [34-36].

Methylenetetrahydrofolate reductase (MTHFR), an essential compound in folate digestion system majorly affects instruction of folic corrosive passageway because of the alteration of methylene-THF to the 5-methyl-THF. The most well-known polymorphisms of the MTHFR quality are C677T and A1298C, which are thought to diminish the catalyst movement prompting a reduction in methyl-THF and to be connected with hyperhomocysteinemia, especially in folate lack. The 677 C→T move (exon 4) causes an amino corrosive substitution from alanine to valine at codon 222 inside of the reactant district of the protein, bringing about MTHFR with diminished action [37]. A few studies have reported that MTHFR variations assume a critical part in infection forms and the weakness to a few issues, including vascular maladies, neural tube imperfections and tumor. The relationship between the MTHFR quality polymorphisms and hereditary powerlessness to disease has been broadly assessed in late concentrates, yet the conclusions are questionable. A few studies have conveyed MTHFRC677T gene variation of genotype homozygous SNPs was connected to the expanded CRC danger [38]. In other case, MTHFR 677TT genotype was describe in different studies and report that people could diminished CRC danger, while others watch on no account relationship between the genotype and hereditary vulnerability of MTHFRC677T to CRC and gastric cancer [39, 40].

The Single Nucleotide Polymorphisms (SNPs) in qualities that had able to code for all these proteins could influence the amassing of nucleic acid injuries in the mucosa at the site of infected colorectal, accordingly impacting CRC hazard [41]. From every single polymorphism in these proteins, APE1 Asp148Glu, XRCC1 Arg399Gln and OGG1 Ser-326Cys were record commonly and all around concentrated on [42]. Despite the information that the correlation of many genes like XRCC1 quality polymorphisms and cancer of colorectal hazard was conflicting [43, 44, 45]. Concentrates polymorphism on concentrated promoter with some genes are uncommon, and there is only few articles which revealed that genes had genotype considered as a defensive element in disease of lung and other study demonstrating the variation G allele is connected as an essentially diminished danger for other cancers like glioblastoma[43]. Wide genomic affiliation articles examining quality SNPs and colorectal cancer hazard led in few years distinguished XRCC1 gene amid many others polymorphisms inside of repairing system of DNA loci, yet uncovered that there is definitely absent of correlation between this SNPs and cancer hazard [46]. Another investigation considered numerous SNPs in various distinct qualities with demonstrated defensive impact of variations of XRCC1 as homozygote. Association between all these vitalex planations quality SNPs and cancer like colorectal were quiet unverifiable in the Asian populace which the argument of this study to characterize any connections concerning CRC hazard and other main genes that could influence on the health situation of patient like OGG1 Ser326Cysand XRCC1 SNPs in the populace [47].

EXPERIMENTAL SECTION

Subjects

The study populace included 77 growth male patients with CRC (mean of age in years 64±8.7) separated as; (41 with colon malignancy and 36 with rectal disease) and 55 as controls admitted to the Merjan Hospital in term reached out from October 2015 until March 2016. All patients and control were from the Babil with complete demographic and behavioral data. The subjects were coordinated for age and sex. Neurotic affirmation aimed at growth subjects was done, in addition to that the subjects selected as control had no history of tumor.

DNA isolation

DNA segregated from entire blood utilizing Genomic DNA Purification Kit; The Wizard® Genomic DNA Purification Kit is intended for detachment of DNA from white platelets, tissue society cells and creature tissue, plant tissue, yeast, and Gram positive and Gram negative microscopic organisms. The Wizard® Genomic DNA Purification Kit depends on a four-stage process. The initial phase in the sanitization method lyses the cells and the cores. For separation of DNA from white platelets, this stride includes lysis of the red platelets in the Cell Lysis Solution, trailed by lysis of the white platelets and their cores in the Nuclei Lysis Solution. After lysis, the leukocytes were pelleted and processed with proteinase-K and nucleic corrosive was removed after the standard convention.

Genotyping

Genotyping was performed by PCR-RFLP; the genotyping convention for PCR-RFLP was done as taking after; for MTHFR C677T 20 μL response blend containing 5 μL PCR sections and 2 μL 10X cushion at 37°C overnight. The items were processed by 10 U HinfI limitation catalysts (BioLabs Inc., New England) and imagined after electrophoresis on 10% polyacrylamide gels with ethidium bromide. The PCR result of MTHFR A1298C was handled with 10 U MboII limitation catalyst (BioLabs Inc., New England) in a 20-μL response blend containing 5 μL PCR pieces and 2 μL 10X support at 37°C overnight.

Assimilation items were envisioned after electrophoresis on 10% polyacrylamide gels with ethidium bromide. PCR enhancement was performed with 25 μL response blends encompassing 2 μL of genomic nucleic acid, Go Taq polymerase with 12.5 μL, 1 μL groundwork for the preliminary and 6.5 μL ddH2O.

Response circumstances encompassed starting denaturation stage at 95 ℃ for 5 min, after that 30 cycles of denaturation at 95 ℃ for 1 min, toughening for 1 min in 66 ℃ (XRCC1 399), 62 ℃ (MTHFR A1298C), 58 for (MTHFR C677T) and prolongation at 71℃ for 1 min. PCR items were examined by agarose gel electrophoresis and all groundworks utilized as a part of this study was portray underneath in the table 1, figure 4 and 5.

TABLE 1: PCR PRIMERS SPECIFIC OLIGONUCLEOTIDE

Locus	Mutation	PCR primers	bp.
MTHFR	C677T	5'-GAAGCAGGGAGCTTTGAGG-3' 5'-ACGATGGGGCAAGTGATG-3'	152
Digested with 10 U *HinfI* restriction enzyme; TT homozygotes showed two fragments of 98 and 54 bp; CT heterozygotes showed three fragments of 152, 98, and 54 bp; wild-type homozygotes (CC) showed only one band of 152 bp.			
MTHFR	A1298C	5'-AGAGCAAGTCCCCCAAGGA-3' 5'-CTTT GTGACCATTCCGGTTTG-3'	123
Digested with 10 U *MboII*restriction enzyme CC genotype showed a band of 95 bp and a residue of 28 bp, AC heterozygotes showed two bands of 95 and 67 bp and three residues of 28 bp, and AA homozygotes showed a band of 67 bp and two 28-bp			
XRCC1	399	5'-TCCCTGCGCCGCTGCAGTTTCT-3' 5'-TGGCGTGTGAGGCCTTACCTCC-3'	447

RESULTS

Geographic attributes including therapeutic and demographic physiognomies of examination subjects uncovered that there are feeble or no huge contrasts concerning subjects as the cases and controls in relations to sex, age, and history of family in malignancy, smoking and Clinicopathological of colorectal as appeared in table 2.

TABLE 2: Common demographic physiognomies including the study

Criteria	Cancer cases (total: 77)		Control cases (total: 55)	
	No.	**%**	**No.**	**%**
Age				
<64	41.0	53.2	34.0	61.8
>64	36.0	46.8	21.0	38.2
Sex				
Male	52.0	67.5	23.0	41.8
Female	25.0	32.5	22.0	40.0
Smoking condition				
Smoking	68.0	88.3	18.0	32.7
Not	9.0	11.7	37.0	67.3
Clinicopathological of colorectal				
Proximal	17.0	22.1	0.0	0.0
Distal	21.0	27.3	0.0	0.0
Rectal	33.0	42.9	0.0	0.0
No data	6.0	7.8	0.0	0.0

The consequences of RFLP-PCR uncovered the genotype circulations for MTHFR C677T, MTHFR A1298C and XRCC1 in patients with CRC. The appropriation quality polymorphisms in both patients and controls were planned with Hardy-Weinberg balance.

Hereditary polymorphisms of all qualities incorporating into this study were portrayed in figure 1, 2 and 3 and table 3. The Genotype appropriation for MTHFR 677 quality in CRC patients; the recurrence of MTHFR C677 genotypes were as kindred TT 12.0 (15.6%), CT 24.0 (31.2%), and CC 41.0 (53.2%) in CRC, and in the control was 19.0 (34.5%), 14.0 (25.5%), and 22.0 (40.0%) individually. Amalgamation frequencies for MTHFR 677 TT homozygous and CT 677 heterozygous watched were 31.2% in CRC and 47.3% in the controls as appeared in table3.

TABLE 3: Genotype distributions for CRC cases and control participants

MTHFR 677	Cancer cases		Control cases	
	No.	**%**	**No.**	**%**
CC	41.0	53.2	22.0	40.0
CT	24.0	31.2	14.0	25.5
TT	12.0	15.6	19.0	34.5
T allele	48.0	31.2	52.0	47.3
C allele	106.0	68.8	58.0	52.7
MTHFR1298	**Cancer cases**		**Control cases**	
	No.	**%**	**No.**	**%**
AA	47.0	61.0	26.0	47.3
AC	21.0	27.3	21.0	38.2
CC	9.0	11.7	8.0	14.5
A allele	115.0	74.7	73.0	66.4
C allele	39.0	25.3	37.0	33.6
XRCC1 399	**Cancer cases**		**Control cases**	
	No.	**%**	**No.**	**%**
TT	28.0	36.4	27.0	49.1
TG	13.0	16.9	6.0	10.9
GG	36.0	46.8	22.0	40.0
T allele	69.0	44.8	60.0	54.5
G allele	85.0	55.2	50.0	45.5

The Genotype dispersion for MTHFR 1298 quality in CRC patients; the recurrence of MTHFR C677 genotypes were as kindred CC 9.0 (11.7%), CA 21.0 (27.3%), and AA 47.0 (61%) in CRC, while in the control was as individual 8.0 (14.5%), 21.0 (38.2%), and 26.0 (47.3%) separately. The recurrence for MTHFR 1298 quality AA homozygous and AC 1298 heterozygous watched were 74.7% in CRC and 66.4% in the controls as appeared in table 3 and figure 2, 4 and 5.

Spreading of genotype for XRCC1 399 quality in CRC patients; the Genotype dissemination for this quality in CRC patients; the recurrence of XRCC1 399 genotypes were as kindred TT 28.0 (36.4%), TG 13.0 (16.9%), and GG 36.0 (46.8%) in CRC, while in the control was as individual 27.0 (49.1%), 6.0 (10.9%), and 22.0 (40%) separately. The recurrence for XRCC1 399 quality TT homozygous and TG 399 heterozygous watched were 44.87% in CRC and 45.45% in the controls.

Figure 1: Genotype distribution for MTHFR 677 gene in colorectal cancer patients



DISCUSSION

(CRC) is viewed as a noteworthy wellbeing issue: it is the most common disease and the second biggest reason for malignancy demise in Western nations [48]. Customarily, CRC investigation was concentrated for chromosomal insecurity (CIN) passageway, wherein APC quality transformation consider as main pathogenic occasion which can prompts misfortunes of allele associated to translocation and physical quality intensification and that established model of carcinogenetic is in charge of more than 75% from all cases of CRC [49]. The following cancer-causing trail is portrayed with most recent many years in twentieth century, which is identified with deactivation the befuddle reparation quality framework, that thusly prompts inactivation of changed tumor silencer qualities, which is called MSI or MMR passageway. Lynch disorder is the worldview for that option cancer model; a diploid tumor prompts by these disorders that have microsatellite flimsiness (MSI) phenotype. Developing proof recommends that some polymorphisms in the MTHFR quality add to sporadic CRC [50].

Numerous studies done on CRC, have reported a defensive relationship among the genotype of MTHFR 677TT associated with the jeopardy of other disease [51, 52]. Moreover, other concentrate likewise proposed that people with folate sufficient prominence which are consider homozygous for previous gene SNPs require diminished the danger of CRC. Also, others watched that the TT genotype was defensive in folate-loaded subjects, while the blend of TT and low folate status presented no insurance, or even demonstrated an expanded danger. These outcomes recommend that the malignancy hazard connected with MTHFR polymorphisms may show a quality supplement communication that relies on upon the level of folate admission or plasma folate levels. Be that as it may, we couldn't assess the quality supplement collaboration in our study because of an absence of information with respect to the plasma folate levels of case gathering. Despite the fact that we had data on the plasma folate levels of numerous solid people in the control bunch, which depended on the all-inclusive community [53, 54].

The aftereffects of this study displayed an on a very basic level balanced spread of a couple of alleles like (T allele in MTHFR C677T, C allele in MTHFR A1298C) between CRC patients diverged from control. We record a foremost relationship of two polymorphisms in MTHFR with powerlessness to CRC. The affiliation saw between the SNPs in the MTHFR quality and helplessness to CRC has been conflicting. There is a constrained study on that subject which discovered MTHFR polymorphism C677T does not influence the danger of CRC. In any case, the lion's share of studies distributed gave great confirmation that homozygosity to the T-allele is connected with an unassuming however fundamentally diminished danger for this disease. A meta-examination of 20 studies including

10,131 CRC patients and 15,362 controls, recommended that the 677T allele gives a defensive impact against CRC hazard [56]. Also, others distributed a HuGE audit on the MTHFR C677T polymorphism, in which the 677TT genotype gave off an impression of being connected with a lessened danger for CRC [57].

The 19q13.2 site which containing XRCC1 is comprises of many exons encoding a numerous amino acids corrosive enzymatic free atomic protein platform which communicates with enzymatic components, for example, PDRP, DNA polymerase β DNA and ligase III to encourage protein/protein reactions and proficient repair of SSBs DNA [58]. Notwithstanding the point that the polymorphism within XRCC1 Arg399Gln was performed to protect affectability to the DNA repair imperfection and alkylating operators methyl methane sulfonate in the cell line EM9 lacking XRCC1, the conflicting reports in relation to variations of the XRCC1[59]. The fact that conceivable that SNPs of additional reparation potentials, XRCC2for example, which is considered as linkage disequilibrium with XRCC1 Arg399Gln, may possibly adjust impact of this SNPs with the danger of colorectal cancer[60, 61, and 62].

The outcomes on fruitlessness evaluation demonstrated that a large portion of the semen tests from those barren male patients have a place with 20-36 years of age classification have cancellation inside of Y-chromosome area, the thought that that erasure in charge of male barrenness emerges from the clinical perception of the patients' male regenerative framework 63, 64 and 65].

Figure 2: Genotype distribution for MTHFR 1298 gene in colorectal cancer patients





Figure 4: Gel electrophoresis of MTHFR A1298C PCR products. Lane No. 1-6 shows the 123 bp for the gene product, (Ladder) lanes contain the 100 bp DNA Step Ladder, 3% NuSieve® 3:1 agarose gel in 1X TBE buffer containing 0.8µg/ml ethidium bromide



Figure 5: Gel electrophoresis of MTHFRA C677T and XRCC1 PCR products. Lane No. 1-6 shows the MTHFRA C677T 152 bp (down), while Lane No. 1-5 shows the XRCC1 447bp (up) PCR products for the gene, (Ladder) lanes contain the 100 bp DNA Step Ladder, 3% NuSieve® 3:1 agarose gel in 1X TBE buffer containing 0.8µg/ml ethidium bromide

REFERENCES

[1] Pierre RV, Hoagland HC. *Cancer*. 1972; 30[4]:889–94. Epub **1972**/10/01. PMID: 4116908.
[2] O'Riordan ML, Berry EW, Tough IM. *Br J Haematol*. **1970**; 19[1]:83–90. Epub 1970/07/01. PMID: 5453917.
[3] Guttenbach M, Koschorz B, Bernthaler U, Grimm T, Schmid M. *Am J Hum Genet*. **1995**; 57
[4] [5]:1143–50. Epub 1995/11/01. PMID: 7485166; PubMed Central PMCID: PMC1801353.
[5] Jacobs PA, Brunton M, Court Brown WM, Doll R, Goldstein H. *Nature*. **1963**; 197:1080–1. Epub **1963**/03/16. PMID: 13964326.

[6] Chapiro E, Antony-Debre I, Marchay N, Parizot C, Lesty C, Cung HA, et al. *Genes Chromosomes Cancer.* **2014**; 53[3]:240–7. Epub 2014/01/16. doi: 10.1002/gcc.22134 PMID: 24424752.
[7] Riske CB, Morgan R, Ondreyco S, Sandberg AA. *Cancer Genet Cytogenet.* 1994; 72[1]:44–7. Epub **1994**/01/01. PMID: 8111738.
[8] Holmes RI, Keating MJ, Cork A, Trujillo JM, McCredie KB, Freireich EJ. *Cancer Genet Cytogenet*. **1985**; 17[3]:269–78. Epub 1985/ 07/01. PMID: 3859363.
[9] Zhang LJ, Shin ES, Yu ZX, Li SB. *Chin Med J* [Engl]. 2007; 120[22]:2002–5. Epub **2007**/12/11. PMID: 18067786.
[10] Lippert E, Etienne G, Mozziconacci MJ, Laibe S, Gervais C, Girault S, et al. *Haematologica*. 2010; 95[9]:1604–7. Epub **2010**/05/04. doi: 10.3324/haematol.2009.019109 PMID: 20435623; PubMed Central PMCID: PMC2930965.
[11] Wiktor A, Rybicki BA, Piao ZS, Shurafa M, Barthel B, Maeda K, et al. *Genes Chromosomes Cancer*. **2000**; 27[1]:11–6. Epub 1999/11/24. PMID: 10564581.
[12] Wong AK, Fang B, Zhang L, Guo X, Lee S, Schreck R. *Arch Pathol Lab Med*. 2008; 132 [8]:1329–32. Epub **2008**/08/08. doi: 10.1043/1543-2165[2008]132[1329:lotyca]2.0.co;2 PMID: 18684036.
[13] Postma DS. *Gend Med* **2007**; 4 Suppl B: S133–46.
[14] Townsend EA, Miller VM, Prakash YS. *Endocr Rev* **2012**; 33: 1–47.
[15] Ngo ST, Steyn FJ, McCombe PA. *Front Neuroendocrinol* **2014**; 35: 347–69.
[16] Lockshin MD. *Lupus* **2006**; 15: 753–6.
[17] Goldstein JM, Cherkerzian S, Tsuang MT, Petryshen TL. *Am J Med Genet B Neuropsychiatr Genet* **2013**; 162B: 698–710.
[18] Wu YC, Hill RA, Gogos A, van den Buuse M. *Neuroscience* **2013**; 239: 67–83.
[19] Werling DM, Geschwind DH. *Curr Opin Neurol* 2013; 26: 146–53.
[20] Baron‐Cohen S, Lombardo MV, Auyeung B, Ashwin E, Chakrabarti B, et al. *PLoS Biol* **2011**; 9: e1001081.
[21] Luczak ED, Leinwand LA. *Annu Rev Physiol* **2009**; 71: 1–18.
[22] Ober C, Loisel DA, Gilad Y. *Nat Rev Genet* **2008**; 9: 911–22.
[23] Nakamura H, Ando K, Shinmyo T, Morita K, Mochizuki A, et al. *Ann Thorac Cardiovasc Surg* **2011**; 17: 469–80.
[24] Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, et al. *World J Urol* **2011**; 29: 457–63.
[25] Arbeev KG, Ukraintseva SV, Arbeeva LS, Yashin AI. Difference between male and female cancer incidence rates: how can it be explained? In: Nikulin MS, Commenges D, Huber‐Carol C, editors. Probability, Statistics and Modelling in Public Health: New York: Springer; **2006**.
[26] Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. *Cancer Epidemiol Biomarkers Prev* **2011**; 20: 1629–37.
[27] Skaletsky H, Kuroda‐Kawaguchi T, Minx PJ, Cordum HS, Hillier L, et al. *Nature* **2003**; 423: 825–37.
[28] Helena Mangs A, Morris BJ. *Curr Genomics* **2007**; 8: 129–36.
[29] Ginalski K, Rychlewski L, Baker D, Grishin NV. *Proc Natl Acad Sci U S* A **2004**; 101: 2305–10.
[30] Jangravi Z, Alikhani M, Arefnezhad B, Sharifi Tabar M, Taleahmad S, et al. *J Proteome Res* **2013**; 12: 6–22.
[31] Lahn BT, Page DC. *Science* **1999**; 286: 964–7.
[32] Siegel R, Naishadham D, Jemal A. CA *Cancer J Clin*. **2013**;63(1):11-30.
[33] Witte JS. *Nat Rev Genet*. **2009**;10(2):77-82.
[34] Vogelstein B, Kinzler KW. *Nat Med.* **2004**;10(8):789-99.
[35] Faith JJ, Hayete B, Thaden JT, Mogno I, Wierzbowski J, Cottarel G. *PLoS biology*. **2007**;5(1):e8.
[36] Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R. *BMC bioinformatics*. **2006**;7 (Suppl 1):S7.
[37] Butte AJ, Kohane IS. *Pac Symp Biocomput*. **2000**:418-29.
[38] Li H, W.L. Xu, H.L. Shen, Q.Y. Chen, L.L. Hui, L.L. Long and X.L. Zhu. *Genetics and Molecular Research* 10 (4): 3738-3746 (**2011**)
[39] Shannon B, Gnanasampanthan S, Beilby J and Iacopetta B (**2002**). *Gut* 50: 520-524.
[40] Vollset SE, Igland J, Jenab M, Fredriksen A, et al. (**2007**). *Cancer Epidemiol. Biomarkers Prev*. 16: 2416-2424.
[41] Zeybek U, Yaylim I, Yilmaz H, Agachan B, et al. (**2007**). *Cell Biochem. Funct.* 25: 419-422.
[42] Brevik A, Joshi AD, Corral R, Onland-Moret NC, Siegmund KD, Le Marchand L, Baron JA, Martinez ME, Haile RW, Ahnen DJ, Sandler RS, Lance P, Stern MC. *Cancer Epidemiol Biomarkers Prev* **2010**; 19: 3167-3173
[43] Wilson DM, Kim D, Berquist BR, Sigurdson AJ. *Mutat Res* **2011**; 711: 100-112.
[44] Gsur A, Bernhart K, Baierl A, Feik E, Führlinger G, Hofer P, Leeb G, Mach K, Micksche M. *Cancer Epidemiol* **2011**; 35: e38-e41
[45] Kershaw RM, Hodges NJ. *Mutagenesis* **2012**; 27: 501-510.
[46] Canbay E, Cakmakoglu B, Zeybek U, Sozen S, Cacina C, Gulluoglu M, Balik E, Bulut T, Yamaner S, Bugra D. *Curr Med Res Opin* **2011**; 27: 1295-1302.

[47] Zhou K, Hu D, Lu J, Fan W, Liu H, Chen H, Chen G, Wei Q, Du G, Mao Y, Lu D, Zhou L. *BMC Cancer* **2011**; 11: 104.
[48] Theodoratou E, Montazeri Z, Hawken S, Allum GC, Gong J, Tait V, Kirac I, Tazari M, Farrington SM, Demarsh A, Zgaga L, Landry D, Benson HE, Read SH, Rudan I, Tenesa A, Dunlop MG, Campbell H, Little J. *J Natl Cancer Ins*t **2012**; 104: 1433-1457.
[49] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. *Int J Cancer* **2015**; 136.
[50] Pino MS, Chung DC. *Gastroenterology* **2010**; 138: 2059-2072.
[51] Lengauer C, Kinzler KW, Vogelstein B. *Nature* **1998**; 396: 643-649.
[52] Huang Y, Han S, Li Y, Mao Y, Xie Y: *J Hum Genet* **2007**, 52(1):73-85.
[53] Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R: *Cancer Res* **1997**, 57(6):1098-1102.
[54] Jiang Q, Chen K, Ma X, Li Q, Yu W, Shu G, Yao K: *Cancer Detect Prev* **2005**, 29(2):146-154.
[55] 31. Chen J, Giovannucci EL, Hunter DJ: *J Nutr* **1999**, 129(2S Suppl):560S-564S.
[56] Huang Y, Han S, Li Y, Mao Y, et al. (**2007**). *J. Hum. Genet*. 52: 73-85.
[57] Taioli E, Garza MA, Ahn YO, Bishop DT, et al. (**2009**). *Am. J. Epidemiol*. 170: 1207-1221.
[58] Canbay E, Cakmakoglu B, Zeybek U, Sozen S, Cacina C, Gulluoglu M, Balik E, Bulut T, Yamaner S, Bugra D. *Curr Med Res Opin* **2011**; 27: 1295-1302.
[59] Brevik A, Joshi AD, Corral R, Onland-Moret NC, Siegmund KD, Le Marchand L, Baron JA, Martinez ME, Haile RW, Ahnen DJ, Sandler RS, Lance P, Stern MC. *Cancer Epidemiol Biomarkers Prev* **2010**; 19: 3167-3173.
[60] Gsur A, Bernhart K, Baierl A, Feik E, Führlinger G, Hofer P, Leeb G, Mach K, Micksche M. *Cancer Epidemiol* **2011**; 35: e38-e41.
[61] Sabreen A. A. Kamal, Ruqaya M. J. Awadh, Ali H. M. Al-Marzoqi. *Journal of Biology, Agriculture and Healthcare*. **2013**. 3 (18): 49-53.
[62] Ali Hussein Al-Marzoqi, Mohammad Aboud M. Mohammad Sabri A. *Journal of Biology, Agriculture and Healthcare*. **2012**. Vol 2 (9): 10-16.
[63] Ali Hussein Al-Marzoqi, Zahraa M. Al-Taee and Nada Khalid Ahmed. *International Journal of Science and Nature*. **2014**. Vol. 5 (1): 1-6.
[64] Ali Hussein Al-Marzoqi, Mohammad Aboud Al-Qaraguli and M. Mohammad Sabri A. *Journal of Al-Qadisiyah for pure science*. **2013** Vol 18 (3): 1-12.
[65] Ali Hussein Al-Marzoqi, Nisreen Kaddim Radi, Ammal Raqib Shamran. *World Journal of Pharmaceutical Research.* **2015**. Vol 4 (4); 102-113.
[66] Ali Hussein Al-Marzoqi, Ammal Ragib Shemran, Raad Abbas Kadhim, Zainab Haider Al-Mosawi, Lina Hassan Alasady, Worood Hamza Aldahmushe, Worood Alwan Al- Jeafry, Shahad Mohammed Darwal, Shahad Muhsen Hattem, Shahad Faddle Hashim. *World Journal of Pharmaceutical Research*. **2015**. Vol 4 (5); 270-276.